Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Lu, Ya; Wang, Xinyue; Gu, Qiang; Wang, Juan; Ying, S.; Wu, Jinjin; Feng, Jifeng

doi:10.1038/s41420-022-01129-8

Cited by 27 publications

(25 citation statements)

References 192 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HnRNPAB is a member of the hnRNP family. Previous studies have shown that hnRNPAB is dysregulated in multiple tumors, which is associated with various malignant phenotypes of tumors (10)(11)(12)31). However, the expression and role of hnRNPAB in NSCLC remain unclear.…”

Section: Discussionmentioning

confidence: 99%

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

et al. 2023

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoprotein A/B (hnRNPAB) is an RNA binding protein that is closely associated with the biological function and metabolism of RNA, which is involved in the malignant transformation of various tumor cells. However, the role and mechanisms of hnRNPAB in non-small cell lung cancer (NSCLC) are still unclear. In the present study, the expression levels of hnRNPAB in NSCLC and normal tissues were analyzed using the human protein atlas database and UALCAN database. The clinical significance of hnRNPAB was assayed using the data of NSCLC cases from The Cancer Genome Atlas database. Subsequently, two stable NSCLC cell lines with hnRNPAB knockdown were constructed and the effects of hnRNPAB silencing on cell viability, migration, invasion and epithelial-mesenchymal transition (EMT) were identified. Genes associated with hnRNPAB expression in NSCLC were screened using the Linked Omics database and verified by quantitative real-time PCR (RT-qPCR). The database analysis indicated that hnRNPAB was mainly expressed in the nucleus of NSCLC cells. Compared with the normal tissues, hnRNPAB expression was overexpressed in NSCLC tissues and was closely associated with the overall survival, sex, tumor-node-metastases classification, and poor prognosis of patients with lung adenocarcinoma. Functionally, knockdown of hnRNPAB inhibited the proliferation, migration, invasion and EMT of NSCLC cells and arrested the cell cycle at G 1 phase. Mechanistically, the bioinformatics analysis and RT-qPCR verification demonstrated that hnRNPAB knockdown led to a significant expression change of genes associated with tumorigenesis. In conclusion, the present study indicated that hnRNPAB played an important role in the malignant transformation of NSCLC, supporting the significance of hnRNPAB as a novel potential therapeutic target for the early diagnosis and prognosis of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, the exact location of site cg15658376 was on chr5, expanding across a large region with distinguished H3K27Ac label, suggesting methylation modification of cg15658376 might silence a possible enhancer of gene heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB). HNRNPAB is closely associated with pre‐mRNAs within the nucleus and is known to regulate pre‐mRNA processing as well as other crucial aspects of mRNA metabolism and transport 26 . hnRNPA0, a main subtype of hnRNP, was found to be a strong promoter for EC 27 .…”

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA‐sequencing and methylation modification data in endometrial cancer

Zhou,

Zhang,

Jin

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

IntroductionEndometrial cancer (EC) is a prevalent malignancy affecting the female population, with an increasing incidence among younger age groups. DNA methylation, a common epigenetic modification, is well‐established to play a key role in cancer progression. We suspected whether DNA methylation could be used as biomarkers for EC prognosis.MethodsIn the present study, we analyzed bulk RNA‐sequencing data from 544 EC patients and DNA methylation data from 430 EC patients in the TCGA‐UCEC cohort. We applied weighted correlation network analysis to select a key gene set associated with panoptosis. We conducted correlation analysis between transcriptomic data of the selected key genes and DNA methylation data to identify valuable DNA methylation sites. These sites were further screened by Cox regression and least absolute shrinkage and selection operator analysis. Immune microenvironment differences between high‐risk and low‐risk groups were assessed using single‐sample gene set enrichment analysi, xCell and MCPcounter algorithms.ResultsOur results identified five DNA methylation sites (cg03906681, cg04549977, cg06029846, cg10043253 and cg15658376) with significant prognostic value in EC. We constructed a prognostic model using these sites, demonstrating satisfactory predictive performance. The low‐risk group showed higher immune cell infiltration. Notably, methylation of site cg03906681 was negatively related to CD8 T cell infiltration, whereas cg04549977 exhibited positive correlations with immune infiltration, particularly in macrophages, activated B cells, dendritic cells and myeloid‐derived suppressor cells. PD0325901_1060 was strongly correlated with risk scores, indicating a potential therapeutic response for high‐risk EC patients.ConclusionWe have developed a robust DNA methylation‐based prognostic model for EC, which holds promise for improving prognosis prediction and personalized treatment approaches. These findings may contribute to better management of EC patients, particularly in identifying those at higher risk who may benefit from tailored interventions.

show abstract

“…22,23 These small molecules can be designed to target an array of actors within the context of splicing, from spliceosome components to diverse trans-acting splicing factors, and even RNA targets themselves, including both regulatory and precursor messenger RNAs. [24][25][26][27][28] In particular, the task of designing small molecules that specifically bind to RNA and modulate splicing is a substantial challenge. Indeed, RNA molecules have markedly fewer hydrophobic surfaces relative to proteins and they present more restricted binding Fig.…”

Section: Introductionmentioning

confidence: 99%

Small molecules modulating RNA splicing: a review of targets and future perspectives

Bouton,

Ecoutin,

Malard

et al. 2024

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Cited by 27 publications

References 192 publications

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis

Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA‐sequencing and methylation modification data in endometrial cancer

Small molecules modulating RNA splicing: a review of targets and future perspectives

Contact Info

Product

Resources

About